In lieu of a rapid IPO bounce back, life sciences lawyers anticipate alternative financings and combinations to pick up in 2023, along with continued momentum for regulatory expertise.
Lawyers who attended the JP Morgan Healthcare Conference in San Francisco earlier this month said the general mood of life sciences stakeholders ranged from “guardedly neutral” to “settled.”